Used in targeted cancer therapies, particularly for gastrointestinal and pancreatic cancers where MUC17 is overexpressed. It serves as a reference in immunoassays to detect and quantify MUC17 expression in tumor tissues. Enables development of diagnostic tools and companion diagnostics for patient stratification. Supports research in antibody-drug conjugates (ADCs) by providing a benchmark for binding affinity and specificity. Facilitates studies on mucin biology and tumor microenvironment interactions. Employed in preclinical validation of therapeutic antibodies targeting epithelial cancers.